English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Osteoarthritis is a syndrome affecting a variety of patient profiles. A European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis and the European Union Geriatric Medicine Society working meeting explored the possibility of identifying different patient profiles in osteoarthritis. The risk factors for the development of osteoarthritis include systemic factors (e.g., age, sex, obesity, genetics, race, and bone density) and local biomechanical factors (e.g., obesity, sport, joint injury, and muscle weakness); most also predict disease progression, particularly joint injury, malalignment, and synovitis/effusion. The characterization of patient profiles should help to better orientate research, facilitate trial design, and define which patients are the most likely to benefit from treatment. There are a number of profile candidates. Generalized, polyarticular osteoarthritis and local, monoarticular osteoarthritis appear to be two different profiles; the former is a feature of osteoarthritis comorbid with inflammation or the metabolic syndrome, while the latter is more typical of post-trauma osteoarthritis, especially in cases with severe malalignment. Other biomechanical factors may also define profiles, such O. Bruyère (&) J.-Y. Reginster Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman B23, 4000 Liège, Belgium e-mail: olivier.bruyere@ulg.ac.be C. Cooper N. Arden E. Dennison MRC Lifecourse Epidemiology Unit and NIHR Nutrition Biomedical Research Centre, University of Southampton, Southampton, UK C. Cooper N. Arden Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK J. Branco CEDOC, Department of Rheumatology, Faculdadede Ciências Médicas, Universidade Novade Lisboa, CHLO, EPE, Hospital Egas Moniz, Lisbon, Portugal M. L. Brandi Metabolic Bone Unit, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy G. Herrero-Beaumont Department of Rheumatology, Bone and Joint Research Unit, IIS-Fundación Jiménez Dı́az, UAM, Fundación Jiménez Dı́az, Madrid, Spain F. Berenbaum Department of Rheumatology, AP-HP, Saint-Antoine Hospital, Pierre and Marie Curie University, Paris, France J.-P. Devogelaer Department of Rheumatology, Saint-Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium M. Hochberg Departments of Medicine and Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, USA J. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Sheffield, UK A. Laslop Scientific Office, Austrian Agency for Health and Food Safety (AGES), Vienna, Austria T. McAlindon Division of Rheumatology, Tufts Medical Center, Boston, MA, USA S. Reiter Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany Drugs Aging (2015) 32:179–187 DOI 10.1007/s40266-015-0243-3

drugs and aging

Erratum to: Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis